Get back to healthy, get back to happy
What we do
Seraphina Therapeutics advances nature and food-based science into evidence-driven consumer products that safely support healthier lives. As a company, we seek to advance products, starting with key fatty acids, that replenish micronutrients and metabolites that our bodies already have but increase in need, especially as we age.
Discover C15
C15:0 (aka pentadecanoic acid) is a trace odd-chain saturated fatty acid present in butter, whole milk, and some fish and plants.A growing body of global, scientific evidence supports C15:0 as a the first essential fatty acid to be discovered in 90 years. You can read the paper here.You’ve met omega-3 and omega-6. Now meet C15:0.
Fatty15
C15:0 (aka pentadecanoic acid) is a trace odd-chain saturated fatty acid present in butter, whole milk, and some fish and plants.A growing body of global, scientific evidence supports C15:0 as a the first essential fatty acid to be discovered in 90 years. You can read the paper here.You’ve met omega-3 and omega-6. Now meet C15:0.
Who we are
We are a consortium of scientists, doctors, dreamers & innovators.We believe that if we can impact health at its core, we can change the world from the inside out.
Stephanie Venn-Watson
DVM, MPH
Co-Founder, Chief Executive Officer
Steph is a serial entrepreneur of for-profit and not-for-profit companies, a veterinary epidemiologist and public health scientist with over 40 patents and 70 peer-reviewed scientific publications, and previously served as an epidemiologist tracking diseases for the Centers for Disease Control and Prevention and World Health Organization.
Eric Venn-Watson
MD, MBA
Co-Founder, Chief Operating Officer
Eric is a practicing physician and entrepreneur. He served over 25 years as a Navy and Marine Corps physician, working with the special forces community to improve their health and fitness. Additionally, Eric founded multiple companies in the drug discovery, healthcare analytics, and medical device industries. He is passionate about developing medical technologies that improve the practice and delivery of healthcare on a global scale.
Kim Kamdar
PhD
Co-Founder, Board Chair
Kim is a Managing Partner of Domain Associates, a life sciences venture capital firm, and has been involved in numerous cutting-edge therapeutic start-ups. She was also a research director at Novartis, where she led a team to uncover small molecules that modulated signaling pathway networks.
Nicholas Schork
PhD
Co-Founder, Senior Scientist
Nicholas is a Distinguished Professor and Director of the Quantitative Medicine and Systems Biology Division at Translational Genomics Institute, an affiliate of The City of Hope. In addition, as a leader in the design and analysis of studies of longevity, Nicholas is Scientific Director for the National Institute of Health’s National Institute of Aging-sponsored Longevity Consortium.
Edward Dennis
PhD
Scientific Advisor
Ed is a Distinguished Professor of Chemistry, Biochemistry and Pharmacology specializing in lipid research at the University of California San Diego School of Medicine. Ed, who is a graduate of Yale University and Harvard University, was Editor-in-Chief of the Journal of Lipid Research and has 375 peer-reviewed publications, including roles of fatty acids in health.
Ronald Krauss
MD
Scientific Advisor
Ron is a Senior Scientist and Director of Atherosclerosis Research at Children’s Hospital Oakland Research Institute and Adjunct Professor in the Department of Medicine at UCSF and the Department of Nutritional Sciences at UC Berkeley. Ron is a graduate of Harvard University, is board-certified in internal medicine, endocrinology and metabolism, and is a Fellow of the American Society of Nutrition and American Heart Association. He has 450 peer-reviewed publications, including leading papers on dairy-based fats and health.